Parker Institute for Cancer Immunotherapy (PICI) shared on LinkedIn:
“Meet Xinyu Xiang, a 2026 Parker Scholar at Stanford University School of Medicine and one of PICI’s Early Career Researcher Awardees.
Xinyu is developing a new platform to generate T cell receptor mimetics that recognize tumor-associated peptide-MHC complexes with high specificity.
Her research combines protein engineering, synthetic co-evolution, and machine learning to systematically discover new binders and expand the range of cancer targets that targeted immunotherapies can recognize.
We’re proud to support Xinyu and the next generation of cancer immunotherapy leaders pursuing bold ideas to transform cancer treatment.
I’m honored and very grateful to receive this award. The support gives me the opportunity to take on a more ambitious direction in my research, and it means a lot to have the potential of this work recognized by the PICI community. – Xinyu Xiang.”
Other articles about Parker Institute for Cancer Immunotherapy on OncoDaily.